GlassScriptPhysician profile
Camilla Tegnander
NPI 1134772882
$701.16
in general payments reported to CMS, 2019-2025
15 companies · $63.04 in 2025
The $63.04 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.41 · 2021: $14.08 · 2022: $22.98 · 2023: $453 · 2024: $137 · 2025: $63.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $313.32 | 2023-2024 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $103.28 | 2023-2024 | Repatha, Otezla |
| Novo Nordisk INC | $37.75 | 2024-2025 | Ozempic, Rybelsus |
| Otsuka America Pharmaceutical, INC. | $29.15 | 2023 | Rexulti |
| Phathom Pharmaceuticals, INC. | $28.98 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $27.74 | 2023-2024 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $27.24 | 2023 | Xarelto |
| Axsome Therapeutics, INC. | $23.85 | 2024 | Auvelity |
| Xeris Pharmaceuticals, INC. | $22.98 | 2022 | |
| Pfizer INC. | $17.08 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $15.55 | 2025 | Breztri |
| Dexcom, INC. | $14.63 | 2023 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $14.12 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $14.08 | 2021 | |
| Lilly USA, LLC | $11.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camilla Tegnander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.